Summary
Efficacy and safety of Canakinumab (Ilaris) in Cryopyrin-Associated Periodic Syndrome (CAPS): Interim results of an onging phase III study
Summary
Efficacy and safety of Canakinumab (Ilaris) in Cryopyrin-Associated Periodic Syndrome (CAPS): Interim results of an onging phase III study
Summary
A study to evaluate the efficacy, response duration and safety of xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU)/Chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine treatment (H1) (NCT01292473)
Summary
A study of the efficacy and safety of Xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU)/Chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine treatment (H1) (NCT01287117)
Summary
A safety study of Xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite treatment with h1 antihistamines, h2 blockers, and/or leukotriene receptor antagonists (NCT01264939)
Summary
Safety study of levocetirizine dihydrochloride oral liquid formulation in children aged 1 to less than 6 years suffering from allergic rhinitis or chronic urticaria of unknown origin (PAL) (NCT00619801)
Summary
Safety study of levocetirizine dihydrochloride oral liquid formulation in children aged 6 months to 11 months (BALL) (NCT00628108)
Summary
Efficacy study for the symptomatic treatment of chronic idiopathic urticaria (NCT00421109)
This site complies with the HONcode standard for trustworthy health information: